Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center Takahiro Fukuda, Michael.

Slides:

Advertisements

Similar presentations

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation Sarah J. Kizilbash, Clifford E. Kashtan,

Advertisements

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates Ian Nivison-Smith, Judy M. Simpson, Anthony.

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Comparison of Allogeneic Hematopoietic Cell Transplantation and Chemotherapy in Elderly Patients with Non-M3 Acute Myelogenous Leukemia in First Complete.

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation David Stephen Shulman, Wendy B. London, Dongjing.

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma Taewoong Choi, Murali K. Kodali, Wen-Kai Weng

Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide,

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation Anne Mette Mørup, Brian.

Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation Kazuko.

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation

Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced Avichai.

Outcome of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Hematopoietic Cell Transplant Recipients Receiving Aerosolized Ribavirin: Significance.

Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival Sangeeta R. Hingorani, Kristy Seidel,

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow.

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer Brigitta Omazic, Mats Remberger, Lisbeth Barkholt, Gunnar.

Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents Andreas Kyvernitakis,

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Betty T. Tran, Abigail Halperin, Jason W. Chien

Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Evaluating the Impact of Antithymocyte Globulin on Lung Function at 1 Year after Allogeneic Stem Cell Transplantation Filippo Milano, Margaret A. Au,

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma George.

Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype Marcie Tomblyn,

Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation Herbert Pichler,

Epidemiology, Management, and Outcome of Invasive Fungal Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation in China: A Multicenter.

Reduced-Intensity Conditioning followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Myelodysplastic Syndrome and Myeloproliferative.

Fluconazole Coadministration Concurrent with Cyclophosphamide Conditioning May Reduce Regimen-Related Toxicity Postmyeloablative Hematopoietic Cell Transplantation

Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial

Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I- Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients.

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Incidence, Predisposing Factors, and Outcome of Engraftment Syndrome in Pediatric Allogeneic Stem Cell Transplant Recipients Irene Schmid, Daniel Stachel,

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Preengraftment Serum C-Reactive Protein (CRP) Value May Predict Acute Graft-versus- Host Disease and Nonrelapse Mortality after Allogeneic Hematopoietic.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

Pretransplant Neutropenia Is Associated with Poor-Risk Cytogenetic Features and Increased Infection-Related Mortality in Patients with Myelodysplastic.

Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation Merav Bar, Weigang Tong, Megan Othus,

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation Sarah J. Kizilbash, Clifford E. Kashtan,

The Contribution of Malglycemia to Mortality among Allogeneic Hematopoietic Cell Transplant Recipients Marilyn J. Hammer, Corey Casper, Ted A. Gooley,

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS Aaron T. Gerds, Ted A. Gooley,

What is quality in a transplant program?

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts Boglarka.

Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical Significance Deborah.

Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents Moreno Festuccia, Kelsey Baker, Theodore.

Prognostic Factor and Quality of Life Analysis in 160 Patients Aged ≥60 Years with Hematologic Neoplasias Treated with Allogeneic Hematopoietic Cell Transplantation

Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome Bart L. Scott, Barry Storer,

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Cytomegalovirus Infection after CD34+-Selected Hematopoietic Cell Transplantation Yao-Ting Huang, Dionysios Neofytos, Julia Foldi, Seong Jin Kim, Molly.

Incidence of invasive aspergillosis after allogeneic hematopoietic stem cell transplantation with a reduced-intensity regimen compared with transplantation.

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based.

Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning

Analysis of Donor and Recipient ABO Incompatibility and Antibody-Associated Complications after Allogeneic Stem Cell Transplantation with Reduced-Intensity.

Frédéric Baron, Effie W. Petersdorf, Ted Gooley, Brenda M

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H

Presentation transcript:

Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center Takahiro Fukuda, Michael Boeckh, Katherine A Guthrie, Debra K Mattson, Stephanie Owens, Anna Wald, Brenda M Sandmaier, Lawrence Corey, Rainer F Storb, Kieren A Marr Biology of Blood and Marrow Transplantation Volume 10, Issue 7, Pages 494-503 (July 2004) DOI: 10.1016/j.bbmt.2004.02.006

Figure 1 Cumulative incidence of invasive aspergillosis (IA), overall survival (OS), and transplant-related mortality (TRM) among allogeneic HCT recipients with or without histories of IA. A, The cumulative incidence of proven or probable IA was significantly higher among patients with histories of IA (broken line; n = 45) as compared with those without prior IA (solid line; n = 2274; 22% versus 7% at day 100; 29% versus 10% at 1 year; P = .001). B, The OS of patients with histories of IA (broken line; n = 45) was significantly worse as compared with those without prior IA (solid line; n = 2274; 56% versus 77% at day 100; 37% versus 58% at 1 year; P = .001). C, The probability of TRM among patients with histories of IA (broken line; n = 45) was significantly higher as compared with those without prior IA (solid line; n = 2274; 38% versus 21% at day 100; 54% versus 32% at 1 year; P = .001). Biology of Blood and Marrow Transplantation 2004 10, 494-503DOI: (10.1016/j.bbmt.2004.02.006)

Figure 2 Invasive aspergillosis (IA) after allogeneic HCT among patients with histories of IA. A, The cumulative incidence of proven or probable IA was significantly higher among patients with histories of IA who received pretransplantation antifungal therapy (Rx) for ≤30 days (broken line; n = 6) as compared with >30 days (solid line; n = 39; 67% versus 15% at day 100; P = .001). B, Among patients with histories of IA that involved the lungs, the cumulative incidence of proven or probable IA was somewhat higher in patients whose pretransplantation chest x-ray (CXR) was abnormal (broken line; n = 19) as compared to those with normal CXR (solid line; n = 16; 32% versus 7% at day 100; P = .064). Biology of Blood and Marrow Transplantation 2004 10, 494-503DOI: (10.1016/j.bbmt.2004.02.006)

Figure 3 Transplant-related mortality (TRM) after allogeneic HCT among patients with histories of IA. A, The probability of TRM was significantly higher among patients with histories of IA who received pretransplantation antifungal therapy (Rx) for ≤30 days (broken line; n = 6) compared with >30 days (solid line; n = 39; 67% versus 36% at day 100; P = .033). B, The probability of TRM was significantly higher among patients with histories of IA who received high-dose (HD) TBI-based conventional conditioning (solid line; n = 31) as compared with those who received non—TBI-based conventional or nonmyeloablative conditioning (broken line; n = 14; 52% versus 14% at day 100; P = .024). Biology of Blood and Marrow Transplantation 2004 10, 494-503DOI: (10.1016/j.bbmt.2004.02.006)

Figure 4 Cumulative incidence of invasive aspergillosis (IA) and overall survival (OS) after allogeneic HCT. Patients with prior IA who were at high risk (defined by pretransplantation antifungal therapy for ≤30 days or abnormal chest x-ray; broken line; n = 22) had a significantly higher incidence of posttransplantation IA (A) and lower survival (B) at 1 year after HCT as compared with those without prior IA (solid line; n = 2274; 45% versus 10%, P = .001; and 23% versus 58%, P = .001, respectively). However, the cumulative incidence of posttransplantation IA (A) and survival (B) among patients with prior IA who were at low risk (defined by pretransplantation antifungal therapy for >30 days and normal chest x-ray; dotted line; n = 23) were not statistically different from those among patients without prior IA (solid line; n = 2274; 13% versus 10%, P = .65; and 52% versus 58%, P = .47, respectively). Biology of Blood and Marrow Transplantation 2004 10, 494-503DOI: (10.1016/j.bbmt.2004.02.006)